Introduction {#hox015s2}
============

The two leading European professional societies in the field of assisted reproduction and medical genetics, the European Society of Human Genetics (ESHG) ([@hox015C61]) and the European Society for Human Reproduction and Embryology (ESHRE) ([@hox015C62]), have been working together since 2004 to evaluate the impact of the rapid progress of research and diagnostic technologies at the interface of assisted reproduction and medical/molecular genetics. Previously, the outcomes of the two consensus meetings have been published ([@hox015C178]; [@hox015C96]) in both society journals. The interdisciplinary expert group (further referred to in this paper as 'the panel') co-opted several new members and met for the third time in Amsterdam (September 21--22; 2016). WHAT DOES THIS MEAN FOR PATIENTS?This paper is the report of a meeting of experts from around Europe to assess how the latest developments in genetics might impact on assisted reproduction.Their discussion included testing for genetic diseases for people wanting to get pregnant and the growth of commercial genetic testing, which may mean that anonymity for people who have donated eggs or sperm cannot be guaranteed. They also considered advances in identifying genetic factors in both male and female infertility and in genetic testing or screening of embryos. They discussed early pregnancy screening and techniques involving mitochondria as well as the impact of IVF on the way genes might work and new techniques for editing, or altering, genes.They concluded that developments in genetics are increasingly relevant in the fertility field as some new techniques are already being used in clinics. They called for international recommendations to consider how new technologies should be introduced into the field of assisted reproduction.

Recently, there have been many research developments in the field of genomics, comprising mainly the ongoing transition from traditional 'monogenic genetics' towards comprehensive testing of the human genome by integrating massively-parallel sequencing (MPS; or synonym 'next generation sequencing') approaches, together with advanced bioinformatics. Currently, it is possible to elucidate the entire single nucleotide-(SNV), copy number-(CNV) and structural (SV) variation of the human genome, i.e. beyond the original medical indication for which a patient (together with his or her family) was referred for genetic testing. These technological advances are being reflected in expanded carrier screening (ECS), voiding of gamete donor anonymity, preimplantation genetic testing (PGT) and non-invasive prenatal testing (NIPT), and in our understanding of the underlying causes of male and female infertility. Likewise, issues related to mitochondrial replacement in human oocytes and to cross-generational epigenetic inheritance or germline genome editing (GGE) technologies are gradually creating paradigm shifts in the field of assisted reproductive technology (ART). Therefore, the panel mainly focused on the aforementioned selected topics, which are currently being or are likely to be introduced into clinical practice.

Recently, transnational registry data provided evidence that the number of ART cycles in Europe is gradually increasing ([@hox015C63]), with more than 640 000 cycles reported in 2012, making a growing contribution to the overall birth-rate in many nations in Europe and beyond. The unprecedented complexity of generated research data and the fast (and often hurried) implementation of new technologies into the fields of assisted reproduction as well as of reproductive genetics render the translation of research results into clinical practice challenging. Therefore, due to the increasing population impact of ART and fast developments in research, the introduction both of novel diagnostics ([@hox015C24]) and therapies into routine ART clinical practice requires prudence and evidence ([@hox015C95]).

It also needs to be acknowledged that there is a blurred boundary between research and its clinical application. Medical and legal liability issues may also arise if the roles and responsibilities of different actors at different stages of translation of research results are not clearly established. Genetic counselling has become increasingly important for patients with various disorders associated with infertility and for future parents to make informed reproductive choices.

The aim of the current consensus paper is to outline the latest developments in ART and genetics/genomics, including their practical implications for clinical management of patients with genetic risks and/or infertility.

ECS in preconception- and gamete donor contexts {#hox015s3}
===============================================

An increasing number of preconception carrier tests for autosomal recessive (AR) diseases have become available for couples who want to achieve a pregnancy. Initially, carrier testing was developed for AR diseases that were frequent in specific ethnic groups (e.g. Tay-Sachs disease in Ashkenazi Jews, hemoglobinopathies in Mediterranean and African populations, and cystic fibrosis in European-derived populations). Various professional societies have recommended preconception carrier testing in high-risk populations (American College of Obsetrics and Gynecology [@hox015C36]) and the American College of Medical Genetics and Genomics 2015 ([@hox015C55]; [@hox015C100]). Given the technological advances in the field of genetic testing, panels for ECS have become broadly available, offering parallel analysis of disease-associated variants in multiple genes, for individuals or couples regardless of their ancestry. A number of such tests are now provided as commercial products, and even within a direct-to-consumer (DTC) setting ([@hox015C19]; [@hox015C2]).

The primary objective of ECS in individuals or couples should be to inform them of possible genetic disease risks for their future offspring and their reproductive options in order to foster autonomous reproductive choices ([@hox015C100]). Although the secondary outcome of broadly offered ECS schemes may decrease the frequency of a target condition, as reported for example in cystic fibrosis ([@hox015C31]), its primary goal is to ensure reproductive autonomy in tested couples. Therefore, non-directive counselling in a pre-and post-test setting is of utmost importance within this context ([@hox015C112]). Still, complex questions may arise if a 'positive' infertile carrier couple would request ART treatment, while rejecting PGD. Would it, then, be morally acceptable or even morally obliged for medical professionals to get involved, given their responsibility to take account the welfare of the possible future child, or to withhold access to assisted reproduction? ([@hox015C500000]).

Readily available ECS requires a proper implementation strategy ([@hox015C100]). In this regard, relevant questions need to be answered first, i.e. what are the responsibilities of healthcare professionals who see couples before pregnancy; which genes and diseases should be tested for; which population groups should be targeted; who will pay for ECS; are couples aware that *de novo* disease-associated variants are not accounted for and that some disease-associated variants (e.g. CNV, SNV) in multiple AR conditions are not examined due to the methodology used and its inherent technical limitations?

To ensure successful implementation of population-based ECS, efforts should be made to increase knowledge about genetic disease (i.e. not only on AR disorders) within primary care, among gynaecologists, obstetricians, and the general public, in order to create appropriate awareness and address personal benefits of screening in a non-directive manner ([@hox015C105]). Such information should include residual risks of tested diseases and age specific risks of *de novo* disease-associated variants ([@hox015C3]). Importantly, dominant *de novo* mutations represent a non-negligible (1--2%) cause of genetic disorders ([@hox015C2]; [@hox015C54]).

The ESHG has recommended that in ECS panels 'priority should be given to carrier screening panels that include (a comprehensive set of) severe childhood-onset disorders ([@hox015C100]). Tests should be designed to achieve high clinical validity (clinical sensitivity, negative and positive predictive values (PPV) and should have established clinical utility'). Current and/or future genome-wide approaches to ECS should also strive to minimise incidental findings ([@hox015C107]) since the capacity of genetic services to provide follow-up counselling is limited (see, for example, the 2013 overview of clinical genetics staffing in selected European countries from a survey conducted by ESHG in 2013: [@hox015C60]). Providers should also take into account individual differences in genetic risk and disease severity perception by the general population. Finally, increasing immigration of non-European populations requires expansion of the disease coverage to those particularly occurring in large immigrant ethnic groups and may pose interpretational and counselling challenges both due to a different spectrum of disease-associated variants (often with unclear phenotypic impact, since there is a general lack of evidence in non-European populations because of the scarceness of respective studies) and to divergent cultural perceptions of examined individuals and/or of their families ([@hox015C57]; [@hox015C18]; [@hox015C105]).

ECS may be of utility for infertile couples when donor gametes are used to allow the matching of the donor with the respective partner ([@hox015C2]; [@hox015C50]). Couples who already have a child with a monogenic condition may also be interested in avoiding other genetic disorders, and consanguineous couples may also benefit from this approach. Consequently, increased use of ECS may lead to an increased use of PGD and thus less frequent requirement of prenatal diagnosis (PND), both leading to a decrease of elective termination of pregnancy (ETP) for severe genetic disease. Furthermore, antenatal ECS and genetic testing in different phases of life may become intertwined. While early offers of preconception ECS may target serious childhood conditions for which PGD or PND are an option to avoid the live-birth of an affected child, ECS may also include treatable conditions (e.g. phenylketonuria or medium-chain acyl-CoA dehydrogenase deficiency) to allow for treatment immediately after birth or even during pregnancy (e.g. 21-hydroxylase deficiency/congenital adrenal hyperplasia) ([@hox015C10]; [@hox015C174]).

Finally, there is increasing evidence that combined low-grade somatic and germline mosaicism eludes current detection techniques and that routine utilisation of blood leukocytes as a proxy for examination of germline variation is insufficient. Therefore, if economically and technically feasible it could be prudent to test in unclear cases genetic variation in the three major embryonic lineages in a given patient in order to estimate the degree of potential post-zygotic mosaicism (i.e. from white blood cells reflecting mesoderm, urine sediment cells---endoderm, and dry buccal swab cells---ectoderm). Nonetheless, even after such a complex genetic testing approach mosaicism cannot be completely excluded. In this regard low-grade undetected parental mosaicism may be responsible for erroneously assigned '*de novo* status' for observed variation and could skew recurrence-risk counselling ([@hox015C28]). Possible germline mosaicism should thus always be mentioned and couples should be informed about the empiric \<1% recurrence risk in simplex *de novo* variants ([@hox015C29]).

Thus, ECS may provide a false sense of reassurance, and the lay and professional public should be duly educated in this regard ([@hox015C100]).

The panel recommends that national professional organizations in the field of ART and medical/clinical genetics either adopt relevant international guidelines for ECS with modification if required, or develop their own guidelines on how to make ECS responsibly available for their respective populations. The panel also calls upon ECS providers to transparently declare the inherent limitations of the applied methodology.

Advances in genetic testing and voiding of anonymity of gamete donors {#hox015s4}
=====================================================================

Historically, gamete donation has been predominantly anonymous. Moreover, many heterosexual parents choose not to disclose the donor origin to their children, regardless of whether the donation was anonymous or not ([@hox015C167]; [@hox015C17]). Most but not all European countries delegate the decision on whether to disclose to the parents ([@hox015C97]).

Some registries, such as the Donor Sibling Registry ([@hox015C53]), Donor-Conceived Register ([@hox015C40]) and Family Tree DNA ([@hox015C72]), allow donors, donor-conceived children and donor siblings to trace each other through genetic ancestry testing, thus possibly reversing the anonymity of the donor. When both parties have consented to find genetic relatives there is little ethical and legal concern. However, within the context of DTC genetic testing, the discovery of relatives can be accidental and/or relatives may be traced without their prior knowledge or consent. In this regard, DTC genetic testing has already been used by several million people to determine their ancestry ([@hox015C97]). The results of these tests, which are usually provided commercially, enable the consumer to match relatives 'on-line'. This strategy has also already been broadly used by adoptees and foundlings ([@hox015C11]). Moreover, the current affordable costs of DTC genetic testing make it accessible to the majority of consumers in Europe, and beyond.

With the growing use of DTC genetic testing, the anonymity of gamete donors can no longer be guaranteed ([@hox015C97]; [@hox015C213]). It does not suffice for the donors to refrain from entering genetic data into the databank. If any of their relatives do, the donor\'s family can be 'collaterally' identified. Also, children whose parents did not disclose that they were donor-conceived may inadvertently find out about their donor origin. DTC genetic testing may provide interesting information regarding an individual´s ancestry (although even in this instance there is a potential for serious misuse of such information; [@hox015C1]) and sometimes even useful information on genetic predispositions. Furthermore, donor-conceived children may also find their half-siblings, the donor himself/herself or other relatives through ancestry testing ([@hox015C151]; [@hox015C20]).

Consequently, anonymous gamete donors should be informed that even though the fertility centre or donor agency will strive to protect their identity, their anonymity cannot be absolutely guaranteed. They should be made aware of the fact that even if they do not submit their DNA to one of the donor registries, they themselves or one of their relatives could be identified. Also, the donor\'s own (future) biological offspring may find half-siblings through these registries. Those donating or conceiving with donated gametes should keep this possibility in mind when deciding whether or not to disclose their donor status/donor conception to their relatives. Another emerging issue is related to the fact that identity disclosure reopens substantiated analyses and legal discussions on numerical limits in donor conception regimes in terms of their potential population genetic impact ([@hox015C135]).

The panel recommends that patients undergoing ART treatment with gamete donation should be informed that their children may eventually discover their donor by genetic testing. Furthermore, laboratories offering DTC genetic testing should transparently inform their customers about the potential impact of their services on the possible discovery of non-paternity or unknown family relationships. ART centres that are using anonymous gamete donors need to provide clear information that donors may eventually be traced.

Advances in the genetics of fertility disorders {#hox015s5}
===============================================

The fields of male (MI) and female (FI) infertility have witnessed substantial research advances on the underlying genetic causes of infertility. However, it needs to be noted that MI/FI are of complex multifactorial origin and have a very broad spectrum of clinical manifestations. Moreover, the diagnosis of 'infertility' is generally defined in clinical terms only, with little *a priori* patient stratification involved in scientific studies. Much of the stated research progress is mainly due to the utilisation of MPS and other 'omics' technologies, including state-of-the-art bioinformatics approaches. Nonetheless, despite such advances, current treatment options in MI/FI have not made a substantial progress ([@hox015C16]; [@hox015C94]).

Male infertility {#hox015s5a}
----------------

The algorithm of genetic testing in MI has not changed. Karyotyping (mainly aimed at examination of gonosomal aberrations which are the major cause of MI) is followed by testing of disease-associated variants in the *CFTR* gene and/or Y chromosome microdeletions. However, in \~40% of all cases of MI the underlying genetic pathogenesis is unknown, 'idiopathic MI' ([@hox015C116]). Genetics might play a role but there still needs to be progress in the understanding of the roles of environmental factors, for example obesity or endocrine disruptors ([@hox015C8]), smoking and air pollution ([@hox015C16]) and epigenetic mechanisms (see further). Another factor which is important to take into account in western populations is the increasing paternal age and the concurrent increase of *de novo* germline disease-associated variants ([@hox015C82]).

Recently, a 9-year prospective study from a single centre, comprising 1737 cases, has identified major causes of MI in 40% of all patients with regards to 'reduced total spermatozoa counts' ([@hox015C158]). Additional progress was brought by proteomics and expression profiling analyses ([@hox015C30]), including the study of relevant animal models (e.g. Mouse Genome Informatics) ([@hox015C134]) and of the reproductive tract microbiome ([@hox015C71]). However, application of research outcomes into routine clinical practice has been hampered by unclear definitions of MI cohorts under study, including unclear specification of 'idiopathic MI' (i.e. what exclusion criteria were applied, what exclusion tests were utilised?), which precludes replication or evidence-based meta-analyses ([@hox015C106]). Another confounding factor is related to the fact that many studies use different standards for sperm analyses and do not always adhere to the standardised World Health Organization criteria ([@hox015C106]).

The association of SNV variation ([@hox015C9]), drawn from genome-wide association studies (GWAS) in MI, is often based on small cohorts ([@hox015C116]). Nonetheless, there has been marked progress in the identification of disease genes and disease-associated variants in 'non-syndromic' MI. Some of the more prominent instances include teratozoospermia in its rare forms characterised by globozoospermia with disease-associated variation detected in *DPY19L2* ([@hox015C75]); *SPATA16* ([@hox015C58]), macrozoospermia in *AURKC* ([@hox015C13]), alterations of sperm flagella in *TUN-STBG1* (Viville *et al.*, 2017; personal communication) and asthenozoospermia in *DNAH1* ([@hox015C7]), *CATSPER1*, *GALNTL5* ([@hox015C186]). In the case of spermatogenic failure characterised by azoospermia and/or oligozoospermia there has also been progress in terms of identification of disease genes comprising for example *TEX11, NR5A1, NR0B1, TEX15* ([@hox015C147]) and *MAGEB4, NANOS1, NR5A1, SOHLH1, SYCE1, TAF4B, WT1 *and* ZMYND15* (in alphabetical order) (see Table [I](#hox015TB1){ref-type="table"} for gene names). Interestingly, *TEX11* is an X-linked gene with both SNV and CNV hemizygous disease-associated variants, causing female-transmitted male meiotic arrest ([@hox015C209]). Although there is no predominant disease-associated variation observed thus far, from the clinical point of view identification of such variation associated with spermatogenic failure could indicate the utility of sperm cryopreservation at an appropriate age, to preserve fertility in individuals involved. Novel targeted biomarker assays are under development ([@hox015C16]), which could improve genetic counselling and patient stratification for targeted ART treatment. Table IList of selected genes involved in male and female infertility.Gene abbreviationNameMIMHGNCGCIDDiagnosisMale infertility *AURKC*Aurora Kinase C60349511391GC19P057230macrozoospermia *CATSPER1*Cation Channel Sperm Associated 160638917116GC11M066034asthenozoospermia *CFTR*Cystic Fibrosis Transmembrane Conductance Regulator6024211884GC07P117465obstructive azoospermia *DNAH1*Dynein Axonemal Heavy Chain 16033322940GC03P052350asthenozoospermia *DPY19L2*Dpy-19 Like 2 gene61389319414GC12M063558globozoospermia *GALNTL5*Polypeptide N-Acetylgalactosaminyltransferase-Like 561513321725GC07P151956asthenozoospermia *MAGEB4*MAGE Family Member B43001536811GC0XP030260azoospermia *NANOS1*Nanos C2HC-Type Zinc-Finger 160822623044GC10P119029azoospermia *NR0B1*Nuclear Receptor Subfamily 0 Group B Member 13004737960GC0XM030322azoospermia *NR5A1*Nuclear Receptor Subfamily 5 Group A Member 11847577983GC09M124481azoospermia *SOHLH1*Spermatogenesis And Oogenesis Specific Basic Helix-Loop-Helix 161022427845GC09M135693azoospermia *SPATA16*Spermatogenesis Associated 1660985629935GC03M172889globozoospermia *SYCE1*Synaptonemal Complex Central Element Protein 161148628852GC10M133553azoospermia *TAF4B*TATA-Box Binding Protein Associated Factor 4b60168911538GC18P026225azoospermia *TEX11*Testis Expressed 1130031111733GC0XM070528azoospermia *TEX15*Testis Expressed 15, Meiosis And Synapsis Associated60579511738GC08M030808azoospermia *WT1*Wilms Tumor 160710212796GC11M032365azoospermia *ZMYND15*Zinc-Finger MYND-Type Containing 1561431220997GC17P004740azoospermiaFemale infertility *BMP15*Bone Morphogenetic Protein 153002471068GC0XP050910primary ovarian insufficiency *CLPP*Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit6011192084GC19P006369primary ovarian insufficiency *EIF2B2*Eukaryotic Translation Initiation Factor 2B Subunit Beta6064543258GC14P075002primary ovarian insufficiency *FIGLA*Folliculogenesis Specific BHLH Transcription Factor60869724669GC02M070741primary ovarian insufficiency *FMR1*Fragile X Mental Retardation 13095503775GC0XP147912primary ovarian insufficiency *FOXL2*Forkhead Box L26055971092GC03M138944primary ovarian insufficiency *FSHR*Follicle Stimulating Hormone Receptor1364353969GC02M048866primary ovarian insufficiency *GALT*Galactose-1-Phosphate Uridylyltransferase6069994135GC09P034636primary ovarian insufficiency *GFD9*Growth Differentiation Factor 96019184224GC05M132861primary ovarian insufficiency *HARS2*Histidyl-TRNA Synthetase 2, Mitochondrial6007834817GC05P141975primary ovarian insufficiency *HFM1*HFM1, ATP Dependent DNA Helicase Homolog61568420193GC01M091260primary ovarian insufficiency *HSD17B4*Hydroxysteroid 17-Beta Dehydrogenase 46018605213GC05P119452primary ovarian insufficiency *LARS2*Leucyl-TRNA Synthetase 2, Mitochondrial60454417095GC03P045405primary ovarian insufficiency *LHCGR*Luteinizing Hormone/Choriogonadotropin Receptor1527906585GC02M048647primary ovarian insufficiency *LHX8*LIM Homeobox 860442528838GC01P075128primary ovarian insufficiency *MCM8*Minichromosome Maintenance 8 Homologous Recombination Repair Factor60818716147GC20P005926primary ovarian insufficiency *MCM9*Minichromosome Maintenance 9 Homologous Recombination Repair Factor61009821484GC06M118813primary ovarian insufficiency *NOBOX*NOBOX Oogenesis Homeobox61093422448GC07M144397primary ovarian insufficiency *NOG*Noggin6029917866GC17P056593primary ovarian insufficiency *PMM2*Phosphomannomutase 26017859115GC16P008788primary ovarian insufficiency *POLG*DNA Polymerase Gamma, Catalytic Subunit1747639179GC15M089316primary ovarian insufficiency *REC8*REC8 Meiotic Recombination Protein60819316879GC14P024171primary ovarian insufficiency *SMC1B*Structural Maintenance of Chromosomes 1B60868511112GC22M045344primary ovarian insufficiency *SOHLH1*Spermatogenesis and Oogenesis Specific Basic Helix-Loop-Helix 161022427845GC09M135693primary ovarian insufficiency *STAG3*Stromal Antigen 360848911356GC07P100177primary ovarian insufficiency *SYCE1*Synaptonemal Complex Central Element Protein 161148628852GC10M133553primary ovarian insufficiency *TLE6*Transducin Like Enhancer Of Split 661239930788GC19P002976embryonic lethalithy *TUBB8*Tubulin Beta 8 Class VIII61676820773GC10M000048oocyte maturation arrest *TWNK*Twinkle MtDNA Helicase6060751160GC10P100991primary ovarian insufficiencyLegend *GeneCards (GCID)*[www.genecards.org](www.genecards.org) *HUGO Gene Nomenclature Commitee (HGNC)*[www.genenames.org](www.genenames.org) Mendelian Inheritance in Man (MIM)[www.omim.org](www.omim.org)

Awareness of rare genetic syndromes is also relevant in unexplained MI. Although such syndromes are often detected by a medical and family history, typical dysmorphic features, associated disabilities and medical examination, i.e. prior to the diagnosis of MI itself, there could be mild forms of these diseases presenting in adulthood as MI, due to improved standard medical and social care. These clinical entities, for example, comprise hypo-gonadotrophic hypogonadism (Kallmann syndrome---MIM: 308700), where MPS led to the identification of additional candidate genes ([@hox015C160]). Research progress has been made in the case of Klinefelter syndrome by application of testis transcriptomic analysis ([@hox015C38]) MI is also commonly associated with rare syndromes with maldescended testes where most of the progress in research is again due to the application of MPS and bioinformatics: Noonan---MIM:163950 ([@hox015C156]), Cleidocranial dysplasia---MIM:119600 ([@hox015C88]), Bloom- MIM:210900 ([@hox015C123]) and Silver-Russel syndromes - MIM:180860 ([@hox015C77]). Likewise, primary ciliary dyskinesia (MIM: 244400) and myotonic dystrophy 1 (MIM: 160900), which are associated in their milder forms with MI, have been subjected to similar research strategies ([@hox015C128]; [@hox015C169]).

The panel recommends that standardised clinical terminology and inclusion/exclusion criteria for MI should be used to allow replication studies and evidenced-based meta-analyses to move the field forward. Due to rapid progress in research, selected gene panels may soon become a useful tool allowing identification of additional causes of MI, and thus improve genetic- and reproductive counselling, facilitate patient stratification and therefore enable more precise ART approaches.

Female infertility {#hox015s5b}
------------------

In the same way as in MI, research on the underlying genetic causes of FI is quickly advancing. Nonetheless, relatively little is still known about the genetic background of most cases of FI or female subfertility (FSF), and even less is translated into novel clinical practice. Evidently, FI is of complex multifactorial origin as reflected by the clinical and genetic heterogeneity of the cohorts under study, which then hinders replicability of previously performed analyses. Presumably hundreds of genes have to interact in a precise manner during sex determination, gametogenesis, complex hormone actions/interactions, and embryo implantation and its early development, in order to create a healthy offspring. Thus, disorders related to FI/FSF are expected to be highly polygenic ([@hox015C118]). Considering that in mice more than 500 genes have already been associated with FI (MGI, see above) many more disease genes are waiting to be identified in humans in the coming years. Non-coding RNA\'s and epigenetic modifications have also been implicated in the control of ovarian function and thus their disturbances are likely to be associated with FI ([@hox015C153]).

Chromosomal aberrations remain a major known cause of premature ovarian insufficiency (POI) and recurrent miscarriages, thus decreasing the chance of successful pregnancy ([@hox015C210]; [@hox015C191]). A sizeable proportion of disorders of sexual development are also caused by gonosomal aberrations, and for other aetiologies, such as hypothalamic-pituitary-gonadal deficiencies, many additional disease-causing genes have already been identified (Liebaers *et al.* 2014).

There has been some progress in understanding of the role of genetic disease-causing genes in common multifactorial disorders such as polycystic ovary syndrome (PCOS) and endometriosis, each affecting around 10% of women with FI/FSF. In PCOS, better patient stratification and functional genomics could provide novel research avenues ([@hox015C131]; [@hox015C152]), while in endometriosis ([@hox015C211]) abnormal epigenetic mechanisms in stromal cells may play a pathogenic role.

Progress has also been achieved in the identification of monogenic causes of FI/FSF, in particular for 'non-syndromic' POI for which multiple X-linked and autosomal genes have been identified as recently reviewed ([@hox015C166]). POI is highly clinically heterogeneous and is associated either with ovarian dysgenesis reflected by primary amenorrhea, or with secondary amenorrhea. However, the majority of POI cases are 'idiopathic'. Additional disease-causing genes have been identified by candidate gene approaches, GWAS and/or whole exome analyses utilising MPS. However, disease-associated variants in these genes were reported in a rather small number of cases, some being confined to specific populations ([@hox015C118]; [@hox015C153]; [@hox015C159]). Interestingly, recent studies revealed a complex genetic architecture of POI ([@hox015C21]). The authors screened both known and potential candidate genes in a clinically well characterised cohort of patients. Disease-associated variants were found, for example, in *BMP15, FIGLA*, *FOXL2, GALT, GDF9, LHX8*, *NOBOX*, S*MC1β*, *REC8* and *SOHLH1* (in alphabetical order), which fall into transcription factor TGF-β ligand, enzyme and 'meiosis' functional categories ([@hox015C13]). In the latter category, other authors have reported disease-associated variants in *STAG3* ([@hox015C27]), *SYCE1* ([@hox015C41]), *HFM1* ([@hox015C203]), *MCM8* and *MCM9* ([@hox015C47]) (Table [I](#hox015TB1){ref-type="table"} for gene names). From the clinical point of view, variation linked to POI may also predict the risk of a premature menopause in affected families ([@hox015C119]; [@hox015C153]).

The list of disease-causing genes related to 'syndromic' POI, where its pathogenesis is related to other clinical entities, was reviewed elsewhere ([@hox015C159]). In many instances, these multi-system syndromes rather than FI itself lead to the clinical diagnosis and referral for genetic testing, often in the pre-reproductive age. Disease-associated variants in the *FOXL2* gene provide an example. Altered function of this gene causes the blepharophimosis/ptosis/epicanthus inversus syndrome (BPES; MIM: 110100) with or without POI. Progressive external ophthalmoplegia (MIM: 157640) together with other symptoms, including POI, is caused by disease-associated variants in *POLG* thereby implicating mitochondria-related pathology ([@hox015C45]). Disease-associated variants in *GALT* (MIM: 230400 for galactosaemia), *PMM2* (MIM: 212065 for congenital disorders of glycosylation type Ia), *CLPP* (MIM: 614921 for congenital disorders of glycosylation type It), *NOG* (MIM: 185800 and 186500 for symphalangism 1a and multiple synostoses syndrome 1, respectively), *EIF2B2* (MIM: 603896 for leukoencephaly with vanishing white matter syndrome) and *HARS2* (MIM: 157400 for progressive external ophtamoplegia with mitochondrial DNA (mtDNA) deletions) have also been secondarily implicated in POI (see above) (see Table [I](#hox015TB1){ref-type="table"} for gene names). Likewise, disease-associated variants in several different disease-causing genes (*TWNK, CLPP*, *HARS2, HSD17B4* and *LARS2*); in alphabetical order (see Table [I](#hox015TB1){ref-type="table"} for gene names) are implicated in the development of the Perrault syndrome (MIM: 233400) which associates sensorineural hearing loss and ovarian dysfunction ([@hox015C46]). Finally, CGG-expansions in the 'pre-mutation range' in the *FMR1* gene remain a well established cause of isolated POI, more frequent in families with Fragile X syndrome (MIM: 300624), than in sporadic cases of POI.

Recently, dominant negative disease-associated variants in the *TUBB8* gene, causing defects in spindle assembly and leading to oocyte maturation arrest, have been described in several families. This autosomal disorder was either male-transmitted or *de novo* and its phenotype was female-specific ([@hox015C66]). Disease-associated variants in *TLE6* were linked to preimplantation embryonic lethality ([@hox015C4]). Although the existence of the genuine empty follicle syndrome (GFES) is still a matter of debate, disease-associated variants in the LH/CG receptor gene (*LHCGR*) have been reported in this disorder ([@hox015C212]).

There have also been advances in pharmacogenomics research focusing on the identification of genetic variation related to the individual response to controlled ovarian hyperstimulation (COH). While a number of candidate genes are known, only FSH receptor (*FSHR*) variation (the p.Asn680Ser 'polymorphism') has clinical utility due to its defined predictive value ([@hox015C18500]), and this variation was also linked to some instances of POI ([@hox015C37]).

The panel concludes that the increasing knowledge of the genetic background, together with rapid technological developments, could foster improved diagnostics in FI. This means that in addition to the current routine testing of patients with POI for chromosomal aberrations and *FMR1* pre-mutations, selected gene panels may soon become a useful tool allowing identification of additional causes of FI, and thus improve genetic and reproductive counselling and patient stratification. The same is true for infertile women producing no or only nonviable oocytes or those suffering from premature menopause. Eventually, oocyte donation could be offered in a more personalised manner in FI.

Advances in PGT {#hox015s6}
===============

PGT is defined as the multidisciplinary clinical application of genetic and ART technologies aimed at the examination of a limited number of cells of an embryo in its preimplantation phase of development *in vitro*, i.e. within the context of IVF. PGT is a complex sequential laboratory procedure, which requires multidisciplinary collaboration of ART specialists with laboratory geneticists experienced in the analysis of minimal numbers of cells.

Currently, the arbitrary distinction between the two major PGT modalities, comprising PGD and PGS, is gradually vanishing as genome-wide SNV and CNV variation genetic laboratory testing is being carried out simultaneously from the technical point of view by MPS. This is also reflected by the proposed change of nomenclature for these laboratory procedures within the 'International glossary on infertility and fertility care' which is currently in preparation by the International Committee for Monitoring Assisted Reproductive Technology (ICMART; [@hox015C119]). There, PGT would become the 'root procedural term' to which chromosomal aneuploidy screening/testing (PGT-A) and PGT monogenic disease diagnosis (PGT-M), or any other genetic testing modality, could be annexed.

PGT-M is aimed at diagnosing a specific 'Mendelian' genetic disorder in the embryo for which the prospective parents are at increased risk ([@hox015C190]). PGT-M has an advantage over conventional PND as it precludes the need to consider ETP in an affected ongoing pregnancy.

PGT-A (also known in the literature as PGS, 'PGD for aneuploidy screening/testing/-PGD-AS' or 'PGD for aneuploidy---PGD-A') is aimed at the detection of chromosomal aneuploidy (one or more of the 23 human chromosomes) in order to select (i.e. 'screen') embryos without disease-associated chromosomal aberrations. These embryos are expected to have the highest chance of proceeding to a healthy live-birth. PGT-A is principally carried out to improve IVF efficiency ([@hox015C74]). The beneficial effect of PGT-A utilising 'comprehensive chromosome screening' technology on clinical and sustained implantation rates, in particular in patients with normal ovarian reserve, has been documented in a meta-analysis ([@hox015C39]). However, as the studies included in the aforementioned paper only refer to good prognosis patients, more data are needed to confirm the validity of PGT-A for improving the clinical outcome of PGT-A in other patient categories and various stages of embryo biopsy ([@hox015C95]). It is important to note that since 'IVF success' has been defined by different authors in many ways, it is almost impossible to compare the outcomes of various studies within evidence-based meta-analysis ([@hox015C74]). Better patient stratification prior to PGT-A would help to assess which testing strategy is optimal for specific patient populations. Therefore, currently the beneficial effects of PGT-A do not have a sufficient level of evidence, as the results of standardised RCTs have not been published ([@hox015C95]). Since PGT-A is costly, 'positive' RCT outcomes also commonly represent a prerequisite for PGT-A reimbursement within most European healthcare systems.

Since improved vitrification methods are currently being introduced ([@hox015C192]) and a specific RCT has been carried out ([@hox015C35]), selection of fresh embryos for transfer by PGT is increasingly being replaced by frozen embryo transfer. This approach allows for more time to perform high-quality PGT and aggregate more 'diagnostic cases' for simultaneous examination, which also decreases costs. Essentially, the increased utilisation of evidence-based PGT is intertwined with advances in embryo vitrification and reliant on high-quality expertise in embryo micromanipulation ([@hox015C74]), including properly established indicators ([@hox015C205]).

Whole-genome haplotyping approaches, e.g. karyomapping ([@hox015C141], [@hox015C142]; [@hox015C189]), as well as MPS-based whole-genome 'deep sequencing' allows for concurrent haplotyping, SNV and CNV examination, hence enabling aneuploidy assessment when specific PGT and informatics approaches are applied ([@hox015C214]). Haplotyping enables reliable PGT-M for virtually any inherited disease-associated variants (even without the necessity of a prior work up identifying the respective variants within a given family), while genome-wide low-coverage MPS allows PGT-A, including diagnosis of partial chromosomal aneuploidies down to as little as 1.8 Mbp in size ([@hox015C220]; [@hox015C172]; [@hox015C198]). Whereas most PGT-M testing methods to date had focused on analysing a single locus or a localized region of the genome, novel technical approaches may provide broader examination of an embryo's genomic variation. As a consequence, not only the genetic variants of interest, but also genomic variation unrelated to the original referral and request of the couple, may be detected. This approach opens novel ethical issues to be explored ([@hox015C101]; [@hox015C193]) and subsequently professional guidelines ought to be developed.

PGT, like all forms of clinical genetic testing, requires strict quality assurance and assessment. Regular participation in external quality assessment should be considered as essential and is indeed obligatory for genetic tests in some countries. PGT-specific schemes are readily available for both monogenic and aneuploidy testing in Europe, and beyond. Laboratory accreditation according to ISO15189 is still considered the most effective route to quality assurance ([@hox015C98]) and its uptake is increasing in Europe, and beyond. It needs to be noted that technique-specific guidelines, such as those for diagnostic MPS, are equally relevant and important for PGT and should be observed ([@hox015C129]; [@hox015C127]).

Likewise, the 'Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology' should be observed ([@hox015C162]). Moreover, Human Genome Variation Society recommendations on sequence variant nomenclature and proper assignment of 'disease association' in detected variants (hence reserving the prefix 'pathogenic' only to a clear set of diagnostic situations denoting that a given variant 'causes disease when in a specific context') ([@hox015C102]), including relevant recommendations for the reporting of diagnostic tests, ought to be followed in PGT ([@hox015C34]).

Another issue related to the clinical implementation of PGT-A is due to the fact that embryo mosaicism challenges provision of categorical (or 'conclusive') results. Although trophectoderm (TE; 'Day 5' or 'Day 6') biopsy allows for obtaining 'aggregate' template DNA from multiple embryonic cells, rather than one or two cells within a blastomere ('Day 3') biopsy, it remains merely a general biopsy technique with its inherent limitations regarding the representativeness of the sample drawn in terms of the tissue/organ under study. These limitations are similar to those currently discussed in the domain of cancer, where accurate diagnosis and/or replicable research progress also to a large extent depend on the experience of the biopsy operator and exact position of the biopsy within the tissue of interest ([@hox015C113]). Therefore, the sample of cells obtained by embryo biopsy (at any given developmental stage) might not be representative of the entire embryo, as high rates of mosaicism have been also reported at the blastocyst stage ([@hox015C69]). In conclusion, while MPS improves analytical sensitivity and thus detection of mosaicism in a given embryo biopsy, it does not remedy the limitation that only the cells present in the biopsy are being analysed ([@hox015C170]).

There already are reports on successful pregnancy outcomes following the replacement of selected mosaic aneuploidy blastocysts ([@hox015C5]; [@hox015C86]). This observation, potentially changing the current paradigm of PGT-A, calls for follow-up multicentric studies to this initial observation and to duly prioritise embryos for transfer in terms of quantitative and qualitative parameters of embryo chromosomal mosaicism. The chance of a healthy live-birth will vary depending both on the rate of mosaicism and on the type of aneuploidy (which chromosome, monosomy versus trisomy, are involved). The current challenge in this field is thus to define 'cut-off' levels, allowing to classify embryos as transferrable as first priority (i.e. no mosaicism detected), transferrable as second priority (i.e. moderate level of mosaicism with exclusion of those chromosomes potentially related to viable pathological conditions) and non-transferrable (i.e. excessive level of mosaicism or mosaics including chromosomes potentially related to viable pathological conditions ([@hox015C157])). Therefore, PGT-A could be considered primarily as a 'ranking tool' (i.e. a 'quantitative selection strategy'), rather than a 'screening tool' (i.e. 'qualitative selection strategy'), in order to discern euploid embryos from aneuploid ones ([@hox015C130]).

This important observation leads to further questions about who should decide on the ranking or exclusion of embryos for transfer, and about what information is provided by the genetic laboratory to the ART clinician and IVF laboratory, and the prospective parents ([@hox015C101]). Comprehensive reproductive and genetic counselling with the latter is needed in order to ensure an adequate understanding by couples of the possibilities and limitations of the current genomics and ART approaches related to PGT-A. Infertile couples also need to be made transparently aware of the fact that PGT-A alone cannot increase the live-birth rate per cycle initiated, since it represents a ranking mechanism, not a therapy *per se* ([@hox015C95]). However, secondary outcome measures, such as mitigation of embryo implantation failures, miscarriage rate and cost-effectiveness may be positively affected by performing PGT-A in specific patient populations ([@hox015C74]; [@hox015C172]; [@hox015C139]). PGT-A also allows negative selection of embryos with viable trisomies in selected couples with limited reproductive prospects, for example owing to parental age. As current evidence is limited, more research has to be carried out and data from multicentric RCTs need to be gathered by harmonised methodologies, thereby enabling the proposed 'PGS 2.0' concept ([@hox015C83]; [@hox015C74]; [@hox015C140]; [@hox015C84]). Utilisation of advanced MPS-based technologies allowing sensitive and specific laboratory testing procedures together with the appropriate standardisation of IVF success reporting in accordance with the proposed The International Glossary on Infertility and Fertility Care, 2017; see above ICMART glossary (see above) could foster replicability of RCTs in PGT-A.

Even in the absence of RCTs, PGT-A is currently practised in an increasing number of laboratories globally. As soon as there is proven laboratory technology which can select clearly non-viable embryos based on their chromosome constitution, the application of PGT-A could be considered as a part of medical practice in high-risk cases (e.g. with advanced maternal age). By avoiding inevitable failure of respective ART cycles by deselecting evidently non-viable chromosomally abnormal embryos, PGT-A may mitigate unnecessary suffering of patients, improve the overall efficiency of IVF in the couple involved and decrease unnecessary COH-related costs.

There has been promising research progress in the utilisation of blastocoele fluid (BF) ([@hox015C78]; [@hox015C126]) serving as an alternative source of template DNA for PGT carried out by MPS ([@hox015C219]). BF reflects the chromosome status of the embryo (i.e. of the inner cell mass; ICM), compared to the sampling of TE cells, which represent only the extra-embryonal tissues. BF is sampled by aspiration with a fine needle (blastocentesis), prior to embryo vitrification (see above). It has been documented that the timing of blastocoele re-expansion in vitrified-warmed cycles represents a favourable predictive factor for positive clinical pregnancy outcome: the faster the re-expansion of the blastocoele, the higher the further developmental potential of the blastocyst ([@hox015C122]). Research in this area is ongoing but when technical difficulties are overcome and outcomes of PGT-A following blastocentesis could be independently validated, then BF may become the preferred source of DNA for PGT.

Finally, utilisation of extracellular embryonic 'matrices', for example drawn from spent *in vitro* culture media (CM), represents another research avenue for sampling of template DNA (although likely fragmented) for 'non-invasive PGT'. However, there are concerns that CM are not produced under 'human DNA-free' conditions and/or there remains a possibility that residual DNA from maternal (for example cumulus) cells could be present ([@hox015C73]; [@hox015C90]).

The future of PGT is closely related to the development of novel genome-wide MPS strategies, but also reliant on advances in blastocyst vitrification, together with appropriate embryo micromanipulation expertise of a given IVF centre. The majority of relevant professional guidelines for genetic/genomic testing within the 'postnatal domain' are applicable to PGT, including rigorous adherence to quality assurance.

The panel calls for a balanced view on the current role PGT-A in ART in terms of the overall improvement of IVF efficiency. Currently, PGT-A represents a ranking mechanism, which has documented positive impact in selected patient populations regarding positive secondary outcome measures such as reduction of embryo implantation failures or miscarriage rates.

The panel also calls for a standardised description of IVF success reporting (for example related to live-birth rate) so that current and/or future RCTs related to application of novel PGT-A approaches could be replicated and thus stand up to the requirements of evidence-based medicine, hence in support of the 'PGS 2.0 concept'.

Whole-genome approaches to PGT-A offer the potential to prioritize embryo transfer not only on the basis of the absence of disease-associated (SNV/CNV) variants related to the primary genetic referral and request of the infertile couple, but also the overall genetic constitution of the embryo. However, guidelines on how to use this information in the genetics laboratory are lacking, as are relevant ethical considerations, and thus need to be addressed by professional societies in the near future. Hopefully, novel techniques related to utilisation of BF or spent CM could overcome invasive template DNA sampling of the early embryo for PGT.

Non-invasive PND and prenatal screening {#hox015s7}
=======================================

Similarly to 'procedural' characterisation of PGT (see above), the term NIPT should be generally reserved for the description of genetic technologies utilising the analysis of cell-free 'foetal' DNA (cffDNA) circulating in the maternal plasma ([@hox015C124]). Nonetheless, due to the initial clinical application of NIPT for the detection of selected foetal chromosomal aneuploidies (i.e. for chromosomes 13, 18, 21, X and Y) this term historically coalesced with this primary screening purpose (see below).

The 'foetal fraction' comprises \~10% of cffDNA in the first trimester of pregnancy, and derives from the placenta. NIPT is equivalent to the concept of 'liquid biopsy' of the placenta, with all its diagnostic limitations historically gathered from the utilisation of chorionic villus biopsy ([@hox015C187]; [@hox015C195]) as a source of template DNA in PND. The circulating genetic material of foetal origin can be either used for non-invasive prenatal diagnosis (NIPD) of, for example, monogenic disorders ([@hox015C52]; [@hox015C197]), and/or to 'screen' for foetal chromosomal aneuploidy by NIPT (alternative terminology: non-invasive prenatal screening---NIPS ([@hox015C87])). The term NIPS is more appropriate since this prenatal screening process may also involve pregnant women without *a priori* genetic indication for their testing, such as in population-based screening schemes.

Implementation of NIPS in PND clinical practice has received considerable attention from professional societies which have developed relevant guidelines ([@hox015C206]; [@hox015C111]; [@hox015C87]). Additional reports duly assessed the global outlook and barriers to the implementation of NIPS within the context of PND ([@hox015C136]; [@hox015C23]), including its role in 'post-PGD' ([@hox015C26]) pregnancies. Relevant ethical issues have been reviewed in a joint ESHG/American Society of Human Genetics document ([@hox015C49]) and recently by the Nuffield Council of Bioethics ([@hox015C144]).

NIPS has been widely introduced in the context of prenatal screening for common chromosomal aneuploidies from as early as the 10th week of pregnancy ([@hox015C32]). Low-coverage genome-wide MPS together with advanced (often proprietary) bioinformatic algorithms are often used to determine the number of DNA-fragments from each targeted chromosome in order to determine the probability of foetal chromosomal aneuploidy. Other approaches assess copy-number by microarray or SNV analyses ([@hox015C133]; [@hox015C198]). The main benefit as compared with traditional combined first trimester antenatal screening (cFTS) ([@hox015C200]), which is based on maternal age, ultrasound assessment of foetal nuchal translucency (NT) and selected biochemical biomarkers in maternal blood, are higher detection rates and a much lower percentage of false-positive (FP) results (\~0.1% in NIPS as compared cFTS where it could be up to 5%). NIPS thus reduces the overall number of follow-up invasive PND procedures and potentially iatrogenic miscarriages ([@hox015C145]; [@hox015C188]; [@hox015C80]). Nonetheless, there is increasing evidence that NIPS and cFTS are complementary approaches within the process of complex provision of antenatal screening in low- and high-risk pregnancies. Each approach has its inherent strengths and limitations, as reviewed for cFTS ([@hox015C201]) and for NIPS ([@hox015C193]), that could be pragmatically complemented within a synergistic (for example, contingent) diagnostic strategy ([@hox015C81]). Due to the fact that to date NIPS is not reimbursed by most European healthcare systems, compared to established cFTS regional- or nationwide schemes, such a contigent approach might be cost effective for most solidarity-based healthcare systems. For example, the UK NHS Rapid protocol suggests NIPS in women with a defined cFTS-related risk range, and thus might assure equitable access to antenatal screening ([@hox015C104]; [@hox015C52]).

There are several specific issues related to the implementation of NIPS within broad antenatal screening strategies ([@hox015C121]). The first issue to be taken into account is related to the fact that, unlike NIPD for monogenic disorders, NIPS is not a diagnostic test. Tested individuals need to be aware that accuracy of NIPS is affected by confined placental mosaicism or detection of unexpected maternal chromosomal abnormalities. Thus, NIPS carried out by whole-genome techniques is not only a 'liquid biopsy' of the placenta ([@hox015C6]; [@hox015C198]), but also detects other circulating DNA material, for example originating from circulating tumour cells ([@hox015C15]; [@hox015C168]).

The second issue is related to discussions as to how NIPS optimally fits within a comprehensive prenatal screening policy, taking into account also its cost-effectiveness ([@hox015C138]; [@hox015C89]), and optimisation of its diagnostic yield ([@hox015C155]). A 'contingent' procedure, offering NIPS for intermediate risk cases after cFTS, would be beneficial in terms of costs and mitigate maternal stress following an inconclusive cFTS result. However, both the high sensitivity of NIPS and shorter waiting time are valuable if NIPS is applied as a first-line test. In this regard, studies which assessed the clinical utility of NIPS offered through primary obstetrical care providers to a general population of pregnant women provided evidence that NIPS has a high uptake and that patients understand its basic concept and limitations. The authors concluded that NIPS could be integrated into routine antenatal screening practice in primary care. Moreover, the complementarity of prenatal ultrasound NT measurements within the context of NIPS was also discussed ([@hox015C146]; [@hox015C150]).

The third issue is whether NIPS should be offered for other abnormalities beyond common chromosomal aneuploidies, including sex chromosome abnormalities and clinically significant microdeletions (for example, for the detection of the DiGeorge syndrome; MIM: 188400). However, the rarity, marked genetic and clinical heterogeneity of these conditions, and thus the resulting low PPV, may lead to an undesirable increase in invasive PND procedures to account for more FP results ([@hox015C14]; [@hox015C165]). Such a scenario could undo much of the potential benefits of introducing NIPS, hence addition of other clinical entities into NIPS 'panels' needs to be carefully considered. Nonetheless, some current commercial NIPS assays do include sex chromosome abnormalities and microdeletions, some of which may even have a variable phenotype. In some cases these may be of maternal origin. It is unclear whether informing apparently healthy women about their mosaicism is of clinical utility. As testing for milder conditions may not lead to termination, the clinical utility will depend on whether the findings enable better treatment for the child. On the positive side, parental awareness could enable treatment of some conditions at birth rather than waiting for symptoms to occur to trigger postnatal testing. On the other hand, there are also concerns that benefits may be outweighed by stigmatisation after diagnosis of phenotypically mild sex chromosomal anomalies or microdeletions. More research is needed to clarify this balance ([@hox015C49]). Some NIPS tests may even offer new opportunities for reproductive health, PGT and pregnancy management ([@hox015C198]). In summary, currently improved technology seems to 'push' the development of such testing offers, rather than established clinical utility and/or relevant patient/client perspectives.

The fourth issue is related to the quality of information and counselling with regard to all relevant aspects comprising incidental findings ([@hox015C49]). There is a concern that women are insufficiently made aware of the fact that NIPS is not a diagnostic test and that eventual ETP should therefore not be based on its findings alone, especially in low-risk populations, in which the PPV is significantly lower than in a high-risk population. A 'positive' NIPS result should always be followed by an invasive PND for verification, as in all other prenatal screening approaches.

Among the first applications of NIPD for monogenic disorders was foetal sexing ([@hox015C164]) in X-linked recessive disorders where the identification of a female foetus avoids the need for invasive PND ([@hox015C137]). The first gene-specific NIPD were introduced for paternally inherited autosomal dominant (AD) and AR disorders where parents carry distinguishable disease-associated variants compared to the foetus. For other recessive disorders, the challenge still is to reliably discern between genetic information deriving from the foetus and from the pregnant woman ([@hox015C52]; [@hox015C197]). NIPD could also be used as a follow-up (confirmatory) procedure to PGT-M, mainly as an alternative to PND, in couples who are reluctant to undergo invasive procedures (for example due to repeated IVF failure or parental anxiety) which are associated with a risk of iatrogenically-induced pregnancy loss ([@hox015C26]).

In view of future scenarios of non-invasive whole-genome NIPS, there is a need for debate about the overall scope of antenatal screening, also taking account of the informational privacy interests of the future child ([@hox015C51]; [@hox015C44]). The possibility of foetal therapy might also impact on the indications for NIPD/NIPS in the near future. Should intrauterine treatment become possible for an increasing number of genetic conditions, including for example Down syndrome ([@hox015C43]), then the informed decision needs to take into account such 'dual goals' of antenatal screening, be it cFTS or NIPS, or their combination.

The panel recommends that future interdisciplinary discussions are carried out between respective professional societies which are responsible for the implementation of non-invasive antenatal screening policies and their potential association with the development of appropriate antenatal therapies. Individuals undergoing NIPS testing should be made aware of the fact that its positive results need to be confirmed by invasive PND. Moreover, tested individuals should be made aware that NIPS using whole-genome approaches may detect 'incidental' findings, for example circulating tumour DNA in the mother. Finally, technological advances foster broader clinical implementation of NIPD as a more acceptable alternative to standard PND associated with invasive sampling of foetal cells or tissues.

Mitochondria: from diagnosis to treatment {#hox015s8}
=========================================

Preventing transmission of mtDNA disease-associated variants {#hox015s8a}
------------------------------------------------------------

It is now technically possible to accurately establish the mtDNA disease-associated variant load (henceforward in legacy terminology 'mutation load') in different types of samples, including embryo biopsies and amniotic fluid, and therefore select an embryo/foetus with a mutation load below the threshold considered as 'pathogenic' when performing PGT-M and PND. Therefore, PGT-M and PND may be used to lower the risk of a child affected by various mitochondrial disorders ([@hox015C148]; [@hox015C163]). However, this 'selective' approach suffers from several drawbacks. One important issue is that there remains uncertainty whether the mutation load found in the tested sample is consistently representative of the rest of the embryo/foetus. Also, the mutation load may change during embryonic/foetal development, and it is difficult to establish the cut-off value for selection because of the uncertainty in correlation between the mutation load and resulting clinical symptoms. Finally, from a clinical point of view, there may be questions on the efficiency of this approach, as there is no guarantee that a woman with a given heteroplasmic load in her somatic tissues produces oocytes with a sufficiently low mutation load for a successful PGT cycle ([@hox015C99]).

To address this issue, mitochondrial replacement therapy (MRT) has been developed ([@hox015C207]; [@hox015C161]). It consists of the transplantation of pronuclei, meiotic spindle or polar bodies of the patient\'s oocytes to the cytoplasm of enucleated donor oocytes, which are presumed to contain 'healthy' mitochondria. Pronuclear transfer was first performed in the mouse ([@hox015C132]), but the resulting offspring showed high levels of mitochondrial carryover ([@hox015C207]). A second approach is based on transplanting pronuclei shortly after completion of meiosis rather than shortly before the first mitotic division, which results in lower mtDNA carryover ([@hox015C163]; [@hox015C108]).

The spindle transfer technique was pioneered in the *Rhesus* monkey, where it proved to be efficient and safe ([@hox015C185]). The feasibility of mtDNA replacement by spindle transfer has also been demonstrated in the human, although some of these oocytes displayed abnormal fertilization ([@hox015C184], [@hox015C183]). The first birth of a child after spindle transfer was reported in a mother who carried a mtDNA mutation causing Leigh syndrome (MIM 256000) that resulted in four pregnancy losses and two deceased children. Although the child born after spindle transfer had a mutation load of 5.7% and was doing well at the time of reporting, long-term follow-up is necessary ([@hox015C216]). The first clinical pronuclear transfer in human oocytes with the result of a healthy birth was carried out in China. It was initially reported at the annual American Society of Reproductive Medicine Annual Meeting in 2003, but published only 13 years later ([@hox015C217]). Polar body transfer has been successfully achieved in the mouse ([@hox015C207]) and recently also in humans ([@hox015C218]). However, there are inherent technical difficulties as polar bodies experience a brief lifetime owing to apoptotic pressures that lead to DNA fragmentation and degradation ([@hox015C207]). Overall, given the experimental nature of all these approaches, PGT and/or PND should always be considered after MRT, as an extra 'safety net' testing procedure.

Ethical issues under discussion include the acceptability of modifying the human genome ([@hox015C149]), the role of the mitochondrial donor as a contributor to the 'parental project' (i.e. concept of 'three parent families' in the lay press) and implications for offspring identity, the proportionality of developing MRT technology as based on a view of the importance of genetic parenthood, and finding a balance between taking appropriate precautions and hampering innovation ([@hox015C143]; [@hox015C22]; [@hox015C68]; [@hox015C85]).

Autologous germline mitochondrial transfer to enhance/improve embryo development {#hox015s8b}
--------------------------------------------------------------------------------

Mitochondrial supplementation methods were introduced about two decades ago with the aim of overcoming poor oocyte quality and repeated IVF failure ([@hox015C12]). Despite the promising success rates of these first experimental trials, further research was largely abandoned because of safety concerns, particularly after such procedures resulted in 45,X pregnancies. Articles evidencing the existence of adult oogonial (oocyte-generating) stem cells in mice, and possibly in women ([@hox015C204]), have re-opened the prospects of delivering a source of pristine and patient-matched germline mitochondria to boost egg health and embryonic developmental potential without the need for young donor eggs to obtain 'healthy cytoplasm' ([@hox015C208]). However, broader clinical experience with this procedure is limited and the existence and role of adult oogonial stem cells in the human is still a matter of professional debate ([@hox015C5]; [@hox015C59]).

mtDNA copy number as a marker of embryo viability {#hox015s8c}
-------------------------------------------------

The mtDNA quantity in TE and blastomere biopsies has been associated with advanced female age and chromosomal aneuploidy, and proposed to provide an independent measure of embryonic implantation potential ([@hox015C48]; [@hox015C70]). The quantity of mtDNA appears significantly higher in embryos from older women and in aneuploid embryos, independent of the patient age. Blastocysts that successfully implant contain lower mtDNA quantities than those failing to implant, with a mtDNA quantity threshold above which implantation was never observed. However, many embryos that failed to implant also had mtDNA amounts below the said threshold. A recent study was not able to confirm these results, and found no statistically significant differences in blastocysts grouped by chromosomal ploidy, maternal age or implantation potential after application of a mathematical correction factor ([@hox015C199]).

Conversely, it has been demonstrated that mtDNA is being reduced in the preimplantation embryo prior to its subsequent increase during the blastocyst stage ([@hox015C179]). To allow proper extrapolations from TE biopsies, it would be necessary to study the correlation between mtDNA content in the TE and the ICM of the blastocyst. Finally, it may be of value to measure the mtDNA content in a Day 3 embryo growing *in vitro* to improve identification of viable embryos with a high developmental potential ([@hox015C180]).

The panel concluded that application of various mitochondria-related procedures in ART still lack a sufficient level of evidence, and that further basic and translational research is necessary in this regard. Furthermore, relevant ethical issues need to be taken into consideration prior to the applications of these technologies in clinical practice.

Epigenetic inheritance-related issues in ART {#hox015s9}
============================================

Even though multiple definitions can be found for epigenetic inheritance, the most accepted one is as follows 'any potentially stable and heritable change in gene expression that occurs without a change in DNA sequence' ([@hox015C91]; [@hox015C171]). Epigenetics involves controlling the structure of the chromatin and the switching between an open to a closed configuration, thereby affecting transcription. Different modifications take place, such as covalent modification of DNA by methylation and/or post-translational modifications of proteins associated with DNA, mainly the histones ([@hox015C177]). So far, most experimental studies in the field of epigenetic inheritance have been performed using mouse models ([@hox015C115]). This implies that application of their outcomes to humans needs to be further substantiated.

Major epigenetic changes responsible for erasure and renewed establishment of the human epigenome occur during gametogenesis and early embryo development. These complex molecular processes include post-fertilization reprogramming to generate a totipotent zygote and are followed by germline reprogramming to generate gametes ([@hox015C175]). These processes together with environmental influences on the formation of human epigenome, especially during early development, are well documented ([@hox015C67]; [@hox015C65]). Consequently, there is a possibility that some ART procedures may inadvertently alter the gamete- and/or embryonal epigenome and potentially generate adverse medical consequences in the offspring.

The epigenetic mechanisms in gametes remain more or less a 'black box' at present, especially regarding oogenesis. In mice, it has been shown that sperm DNA can be methylated and hydroxymethylated, but the exact role of such methylation processes is unclear. It is believed that methylation could both have a global impact on DNA stabilization and a specific purpose, i.e. to silence (imprint) specific genes. It has also been shown that some specific genomic loci will keep their histones during meiosis, instead of exchanging them for protamines, and that this molecular mechanism is correlated with hypomethylation. It is hypothesized that the genes escaping protamination are the ones that need to be expressed very early during embryonic development ([@hox015C92]). After fertilization, paternal DNA is actively demethylated, but some loci remain methylated (mainly in the case of imprinted genes). Thus far, the role of sperm DNA methylation in future embryonic development is not well understood ([@hox015C117]).

The level of DNA methylation in the oocyte is half of that in spermatozoa. DNA methylation in the oocyte does not play a role in the regulation of gene expression of the oocyte itself, but is important for embryonic development ([@hox015C33]). Interestingly, regions that are methylated in the oocyte are more likely to be also methylated in the embryo ([@hox015C176]). These complex processes might be regulated by incomplete demethylation during the post-fertilization reprogramming of the maternal allele or another kind of memory mechanism and present a potential way of epigenetic intergenerational inheritance of environmentally induced (e.g. by COH and/or CM) alterations in DNA methylation patterns of the oocyte ([@hox015C127]).

Another function of DNA methylation in the germline is to control the expression of transposable elements (TPE). These are ancestral traces of retroviruses, representing approximately one-half of the human genome. TPE are reactivated during primordial germ cell formation and early development, and are tightly controlled not to jump 'anywhere' in the genome. The pathway(s) controlling the expression and transposition of TPE are not fully understood, thus far. However, in the mouse, potentially pathogenic alterations of proteins involved in their control can cause MI, mainly by a meiotic blockage at the pachytene stage ([@hox015C79]; [@hox015C215]). Recently, there is also growing evidence on the implication of TPE in various human diseases ([@hox015C93]).

Animal studies have shown that ART procedures may be associated with multiple alterations in gene expression and DNA methylation, mainly of imprinted genes ([@hox015C182]). However, the potential relationship with phenotypic outcomes (if any) remains largely unknown. Also in human studies, epigenetic alterations associated with ART have been reported in embryos and placental tissue or umbilical cord blood ([@hox015C194]). However, these alternations have not yet been unambiguously associated with any clinically relevant outcomes, thus far. Future studies should focus on the normal epigenetic regulation in human gametes and embryos, the natural inter-individual variation in, for example, DNA methylation, the consequences of slight alterations in DNA methylation and phenotypical (long-term) consequences of epimutations ([@hox015C25]).

Recently it was suggested that there is inter-individual variation in susceptibility to environmentally mediated epigenetic alterations in humans ([@hox015C76]). Furthermore, the environmentally induced epimutations occur possibly on a stochastic basis ([@hox015C42]) making 'one-to-one' associations between an environmental clue and epigenetic alterations at a specific gene or set of genes less informative. This observation might also explain inconsistencies found between various studies. ART-induced epigenetic alterations, if they exist, might thus occur at random places in the genome, in only a subset of vulnerable subjects, probably leading to a wide range of adverse phenotypic consequences, which would complicate research on the potential epigenetic effects of ART ([@hox015C42]). Finally, it needs to be noted that these follow-up studies are also hampered by common parental unwillingness to disclose previous IVF-treatments, including data security concerns regarding relevant patient registries.

The panel concluded that more research is needed on the potential impact of specific ART procedures on the epigenome and its consequences for the offspring, including possible epigenetic inheritance pathways. In addition, standardisation of follow-up methodologies and post-IVF patient registries could overcome complex biological issues and foster replicability of initial observations of adverse epigenetic inheritance-related phenomena in children/adults conceived by IVF. Furthermore, relevant social and ethical issues related to this issue need to be explored.

Germline genome editing {#hox015s10}
=======================

Genome editing using tools allowing for exact modification, such as zinc-finger nucleases and TALENs (transcription activator-like effector nucleases), have been available for many years and have been widely used in research ([@hox015C154]). However, with the recent introduction of the CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/Cas9 nuclease) system, genome editing has become much simpler, cheaper and more efficient, opening the road to somatic gene therapy and eventually also GGE ([@hox015C196]).

GGE can be performed in different germ cell types, such as spermatogonial stem cells, *in vitro* matured oocytes, stem-cell derived gametes differentiated *in vitro* from pluripotent stem cell lines obtained after somatic cell nuclear transfer or induced pluripotent stem cells, and even in the early embryo ([@hox015C120]; [@hox015C114]).

GGE at the embryo level has important technical drawbacks, such as incomplete editing leading to mosaic embryos and off-target effects (induced disease-associated variants at sites other than the intended on-target site) that need to be solved before considering possible clinical applications of the technique. As newer, more accurate, efficient, and therefore safer GGE systems are being developed, it is to be expected that these technical limitations could be overcome ([@hox015C110]) as was recently documented in the case of hypertrophic cardiomyopathy ([@hox015C30000]).

Nevertheless, the number of clinical indications that could be envisaged for GGE remediation is limited, thus far, since PGT-M offers an alternative for couples at risk for a genetic disease in their offspring. The potential use of GGE could be envisioned in very high-risk couples, for example if one partner is homozygous for an AD disease, or when both partners suffer from the same AR disorder. Less 'stringent' indications could be in cases where the number of embryos expected to be obtained after PGT-M is small, for example in case of advanced maternal age, or couples at high risk for transmitting more than one genetic disease, or when HLA-matching embryos considered for curing a sibling affected by a severe monogenic disease. Other medical fields also started to discuss the potential implications of GGE ([@hox015C181]). Recently, the American Society of Human Genetics published their position statement on human GGE ([@hox015C50000]) and ESHG and ESHRE are also jointly developing recommendations specific to this topic (de Wert *et al.* 2017 -- 'Responsible innovation in human germ-line genome editing'; personal communication). Furthermore, there is an ongoing debate on the ethical (i.e. the 'slippery slope' argument) and social implications of GGE, and eventually current restrictions on GGE may require a renewed debate ([@hox015C64]; [@hox015C103]; [@hox015C125]; [@hox015C144]). Finally, a transparent and broad collaboration is necessary in order to move the field of GGE responsibly forward ([@hox015C173]; [@hox015C202]).

The panel concluded, that although research in the field of GGE is rapidly developing, its potential medical applications within the context of ART and genetic medicine require further basic and translational research. Consensus guidelines need to be developed by respective professional societies, which will take into account any potentially adverse individual-, population genetic-, ethical- and societal implications of this novel medical technology.

Conclusion {#hox015s11}
==========

The intersection of ART and genomics is a fast growing scientific field, both from the basic and translational research points of view. A selected portfolio of emerging topics was included in the agenda for the third panel meeting, mainly covering issues which have the highest potential of entering, or that are already part of, current clinical practice. As molecular genetic techniques are improved, complete characterisation of the entire human genome variation of an embryo might become a reality. Together with the emergence of therapeutic possibilities comprising, for example, mitochondrial transfer and GGE, professional and ethical discussions around these developments need to be undertaken and international recommendations drawn up in order to determine how such novel technologies ought to be implemented in ART practice in a responsible and evidence-based manner, and accordingly regulated. The panel looks forward to the fourth meeting to discuss these ongoing developments at a European level in the near future.
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